TriVascular Technologies Inc

TriVascular Technologies — Merger or Acquisition (October 2015)

24 slides from TriVascular Technologies's merger presentation, Oct 27, 2015

  1. Slide 1: Combining innovation leaders to revolutionize aortic treatments

    Combining innovation leaders to revolutionize aortic treatments October 26, 2015 Filed by Endologix, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: TriVascular Technologies, Inc. Commission F

  2. Slide 2: Forward-Looking Statements and Additional Information

    Endologix and TriVascular will remain separate operational entities until the closing of the proposed merger transaction. Until closing, Endologix will not offer TriVascular products and TriVascular will not offer Endologix products. The offering referenced herein is not contingent upon the closing

  3. Slide 3: Agenda

    Agenda Corporate values and synergies Overview of Endologix and TriVascular What we will look like together Our new brand Timing/next steps Combining innovation leaders to revolutionize aortic treatments | 10.26.15

  4. Slide 4: The path to our new culture

    The path to our new culture Combining innovation leaders to revolutionize aortic treatments | 10.26.15

  5. Slide 5: Synergy of values

    Synergy of values Patient is #1 Customer centric organization Innovation in our DNA Quality focus Culture demands honesty and integrity Committed to making a difference Financial responsibility Successful integration Combining innovation leaders to revolutionize aortic treatments | 10.26.15

  6. Slide 6: Key features that make this a great merger

    Key features that make this a great merger Combining innovation leaders to revolutionize aortic treatments | 10.26.15 Expanded global sales force Multiple new product launches over next 24 months Broad product offering for AAA An innovation leader with broad clinical indications Significant clinical

  7. Slide 7: AAA disease requires multiple solutions

    Combining innovation leaders to revolutionize aortic treatments | 10.26.15 AAA disease requires multiple solutions

  8. Slide 8: Merger creates one company with multiple AAA treatment options

    Merger creates one company with multiple AAA treatment options Combining innovation leaders to revolutionize aortic treatments | 10.26.15 CAUTION: Nellix is an investigational Device. Limited by federal (United States) law to investigational use only.

  9. Slide 9: Innovative solutions with broad clinical indications (post merger)

    EVAR Innovative solutions with broad clinical indications (post merger) Ultra-low profile Narrow & tortuous iliacs Complex necks Reverse taper Combining innovation leaders to revolutionize aortic treatments | 10.26.15 Preserve bifurcation Tight distal aorta Thrombus EVAS Complete AAA sealing Iliac a

  10. Slide 10: Endologix and TriVascular company snapshots

    Endologix and TriVascular company snapshots Combining innovation leaders to revolutionize aortic treatments | 10.26.15 Location Irvine, CA Santa Rosa, CA Number of employees 614 308 2014 revenue $148 Million $32 Million Commercial reach 44 countries 24 countries Key products AFX, Nellix Ovation

  11. Slide 11: Strong revenue growth with a combined CAGR of 28%

    Strong revenue growth with a combined CAGR of 28% Combining innovation leaders to revolutionize aortic treatments | 10.26.15 Revenue $millions 180 154 111 89

  12. Slide 12: Diversified product revenue (post merger)

    Diversified product revenue (post merger) Combining innovation leaders to revolutionize aortic treatments | 10.26.15 Total Revenue: $190 million Q4 2014 – Q3 2015 AFX 68% Ovation 19% Nellix 13% U.S. 70% International 30% Revenue by geography Revenue by product

  13. Slide 13: Key Product: TriVascular Ovation Prime System

    Key Product: TriVascular Ovation Prime® System 13 Lowest profile FDA-approved catheter Broadest FDA approved IFU Polymer sealing ring creates custom seal and protects the aortic neck Conformable, kink resistant iliac limbs Excellent safety and effectiveness data, including patients with challenging

  14. Slide 14: Key Product: Endologix AFX2

    Key Product: Endologix AFX2® Broad anatomical applicability Tight distal aortas Thrombus laden necks Anatomical fixation with unibody design Preserves native bifurcation and blood flow Eliminates gate cannulation and limb competition ActiveSeal extends the effective seal zone beyond the neck Intuiti

  15. Slide 15: Key Product: Endologix Nellix

    Key Product: Endologix Nellix® 15 Treat more patients Widest patient applicability on IFU Best solution for complex AAA Simplify procedure and planning Limited SKUs More predictable procedure times Intellix™ case planning and management software Designed to reduce endoleaks and secondary interventio

  16. Slide 16: Significant clinical evidence to drive adoption (post merger)

    Significant clinical evidence to drive adoption* (post merger) 2015 2016 2017 Ovation IDE/CAP/PAS (2010) 320 320 320 Global Registry (2011) 501 501 501 LIFE (2014) 200 250 250 LUCY (2015) 20 225 225 Total 1,041 1,296 1,296 AFX IDEs (2000) 707 707 707 PEVAR (2010) 192 192 192 LEOPARD (2015) 150 800 8

  17. Slide 17: Expanded global sales force (post merger)

    Expanded global sales force (post merger) World-class team of trained sales representatives and clinical specialists Significant growth and cross-selling opportunities Customers in 44 countries across five continents Both Combining innovation leaders to revolutionize aortic treatments | 10.26.15

  18. Slide 18: Deep pipeline addressing $2B+ opportunity (post merger)

    U.S. Europe Asia Pacific Latin America Deep pipeline addressing $2B+ opportunity* (post merger) 2015 2016 2017 2018 2019 2020 (Japan) (China) (Japan) (Brazil) (Argentina) (Japan) (Brazil, Argentina) CHEVAS CHEVAS CHEVAS THORACIC * Post-merger estimated regulatory approvals Combining innovation leade

  19. Slide 19: Our commitment: the new Endologix story

    Our commitment: the new Endologix story Combining innovation leaders to revolutionize aortic treatments | 10.26.15 We will maintain a singular focus on the aorta We will continue to uniquely pursue physician-driven innovation We will pioneer and deliver durable EVAR and EVAS solutions We will provid

  20. Slide 20: Treat more patients more effectively: Our new brand identity

    Treat more patients more effectively Our new brand identity

  21. Slide 21: Our new look and feel

    Our new look and feel

  22. Slide 22: Highlights of our future merged company: benefits to key stakeholders

    Highlights of our future merged company: benefits to key stakeholders Combining innovation leaders to revolutionize aortic treatments | 10.26.15 Patients Broadest indications for more on-label treatments Complex AAA and TAA solutions Enabling individualized AAA treatment Customers Aortic innovation

  23. Slide 23: Timing/next steps

    Now – Deal Close Integration planning Communications regarding intended organization Employees Customers Suppliers Partners Timing/next steps Combining innovation leaders to revolutionize aortic treatments | 10.26.15 Post Deal Close Begin integration process Clarify new roles in organization (within

  24. Slide 24: Summary: creating a leader in growth and innovation

    Summary: creating a leader in growth and innovation Combining innovation leaders to revolutionize aortic treatments | 10.26.15 Broadest AAA product line Impressive organizational capability with combined employee base Expanded global sales force Diversified revenue growth New multiple product launch

TriVascular Technologies — Merger or Acquisition (October 2015) on 6ix